中国循证医学杂志

中国循证医学杂志

2017年美国皮肤病学会《皮肤鳞状细胞癌的管理指南》解读

查看全文

皮肤鳞状细胞癌(cutaneous squamous cell carcinoma,cSCC)是人类第二大常见的皮肤肿瘤。近年来,其发病率在全球范围内呈逐年递增趋势。大多数 cSCC 经常规治疗可治愈,但晚期 cSCC 进展快,严重影响患者的生活质量,甚至导致死亡。2017 年,美国皮肤病学会(American Academy of Dermatology,AAD)基于大量循证医学证据制定了最新版的 cSCC 管理指南,包括 cSCC 活检技术、组织病理学评估、临床分级分期、手术和非手术治疗、随访、复发的预防以及晚期 cSCC 管理。本文旨在对该指南进行简要介绍和解读。

Cutaneous squamous cell carcinoma (cSCC) is the second most common human skin tumor. In recent years, the incidence of cSCC is increasing annually. Although most cSCC is curable after basic treatment, the advanced cSCC progresses rapidly and poses a significant risk for the impact on quality of life and death. In 2017, the latest version of cSCC management guideline was developed by the American Academy of Dermatology (AAD) based on extensive evidence-based medical evidence, including cSCC biopsy techniques, histopathological assessment, clinical staging and grading, surgical and nonsurgical treatment, follow-up, recurrence prevention, and management of the advanced cSCC. The purpose of this article is to briefly introduce and interpretate this guideline.

关键词: 皮肤鳞状细胞癌; 管理; 美国皮肤病学会; 指南; 解读

Key words: Cutaneous squamous cell carcinoma; Management; American Academy of Dermatology; Guideline; Interpretation

引用本文: 朱路得, 王佩茹, 张国龙, 王秀丽. 2017年美国皮肤病学会《皮肤鳞状细胞癌的管理指南》解读. 中国循证医学杂志, 2018, 18(4): 289-294. doi: 10.7507/1672-2531.201802023 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Work Group; Invited Reviewers, Kim JYS. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol, 2018, 78(3):560-578..
2. Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol, 2014, 810: 120-140.
3. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol, 1994, 30(5 Pt 1): 774-778.
4. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol, 2013, 68(6): 957-966.
5. Agbai ON, Buster K, Sanchez M, et al. Skin cancer and photoprotection in people of color: a review and recommendations for physicians and the public. J Am Acad Dermatol, 2014, 70(4): 748-762.
6. Linos E, Schroeder SA, Chren MM. Potential overdiagnosis of basal cell carcinoma in older patients with limited life expectancy. JAMA, 2014, 312(10): 997-998.
7. Fosko SW. Counterpoint: Limited life expectancy, basal cell carcinoma, health care today, and unintended consequences. J Am Acad Dermatol, 2015, 73(1): 162-164.
8. Karia PS, Morgan FC, Califano JA, et al. Comparison of tumor classifications for cutaneous squamous cell carcinoma of the head and neck in the 7th vs 8th edition of the AJCC cancer staging manual. JAMA Dermatol, 2017, 154(2):175-181.
9. Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol, 2013, 149(4): 402-410.
10. Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol, 1992, 27(2 Pt 1): 241-248.
11. Leibovitch I, Huilgol SC, Selva D, et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol, 2005, 53(2): 253-260.
12. Goldman G. The current status of curettage and electrodesiccation. Dermatol Clin, 2002, 20(3): 569-578.
13. Lansbury L, Bath-Hextall F, Perkins W, et al. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ, 2013, 347: f6153.
14. Roozeboom MH, Aardoom MA, Nelemans PJ, et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. J Am Acad Dermatol, 2013, 69(2): 280-287.
15. Roozeboom MH, Arits AH, Mosterd K, et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. J Invest Dermatol, 2016, 136(8): 1568-1574.
16. Jambusaria-Pahlajani A, Ortman S, Schmults CD, et al. Sequential curettage, 5-fluorouracil, and photodynamic therapy for field cancerization of the scalp and face in solid organ transplant recipients. Dermatol Surg, 2016, 42(Suppl 1): S66-572.
17. Wang Y, Yang Y, Yang Y, et al. Surgery combined with topical photodynamic therapy for the treatment of squamous cell carcinoma of the lip. Photodiagnosis Photodyn Ther, 2016, 14: 170-172.
18. Kwiek B, Schwartz RA. Keratoacanthoma (KA): an update and review. J Am Acad Dermatol, 2016, 74(6): 1220-1233.
19. Brantsch KD, Meisner C, Schonfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol, 2008, 9(8): 713-720.
20. Cooper JZ, Brown MD. Special concern about squamous cell carcinoma of the scalp in organ transplant recipients. Arch Dermatol, 2006, 142(6): 755-758.
21. Wehner MR, Linos E, Parvataneni R, et al. Timing of subsequent new tumors in patients who present with basal cell carcinoma or cutaneous squamous cell carcinoma. JAMA Dermatol, 2015, 151(4): 382-388.
22. Song F, Qureshi AA, Giovannucci EL, et al. Risk of a second primary cancer after non-melanoma skin cancer in white men and women: a prospective cohort study. PLoS Med, 2013, 10(4): e1001433.
23. Robinson JK, Wayne JD, Martini MC, et al. Early detection of new melanomas by patients with melanoma and their partners using a structured skin self-examination skills training intervention: a randomized clinical trial. JAMA Dermatol, 2016, 152(9): 979-985.
24. Green AC, Williams GM, Logan V, et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol, 2011, 29(3): 257-263.